None listed
Conditions
Interventions
None listed
Sponsors
Nil
Eligibility
Inclusion criteria
Inclusion criteria: The participants recruited in the Phase IV regulatory study
Exclusion criteria
Exclusion criteria: The participants who had physical visits during the lockdown period [22 March 2020 to 26 June 2020 – we received permission from ethics committee to re-initiate the original regulatory study] for the IP [anti-rabies vaccine] administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total number of participants- who have completed the Anti-rabies vaccination [ARV] in pre and during-pandemic •Total number of participants who have not completed the ARV, Reasons for not completing the ARV, if available Number of ARV doses missed by the participants in pre- and during pandemic timelines •Number of total visits missed by the participants including the visits after completion of ARV [visit 6 and 7 which were follow up visits only for the physical examination and no study vaccine administration was required] in both pre and during pandemic period Timepoint: 365 days follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of ARV doses missed by the participants in pre- and during pandemic timelines • Number of total visits missed by the participants including the visits after completion of ARV [visit 6 and 7 which were follow up visits only for the physical examination and no study vaccine administration was required] in both pre and during pandemic period Timepoint: 365 days follow up | — |
Countries
India
Contacts
Public ContactDr Vijaya Chaudhari Gunjal
Seth GSMC and KEMH Mumbai
Outcome results
None listed